Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Charity calls for new focus to combat Hep C infections in Scotland

A charity has called for greater efforts to eliminate Hepatitis C (HCV) from Scotland. There are about 37,000 people living with the virus - but campaigners say as many again are undiagnosed.

Published
27 June 2017
From
BBC
Swiss hepatitis C sufferers to get full access to expensive drug

The Federal Office of Public Health has announced that it will make the hepatitis C drug Zepatier available to all patients from July 1. The 12-week treatment costs CHF31,000 ($31,952) per patient and was previously only available to those with an advanced form of the disease.

Published
26 June 2017
From
swissinfo.ch
New pangenotypic hepatitis C drug combinations recommended for approval in the European Union

Two new pangenotypic direct-acting antiviral combinations have received positive opinions from the scientific committee of the European Medicines Agency (the CHMP) and should receive European

Published
26 June 2017
By
Keith Alcorn
European CHMP Adopts Positive Opinion for Gilead’s Vosevi® (Sofosbuvir/Velpatasvir/Voxilaprevir) for the Treatment of All Chronic Hepatitis C Genotypes

Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Vosevi®, an investigational, once-daily, single tablet regimen of sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of chronic hepatitis C virus (HCV)-infected patients.

Published
26 June 2017
From
Gilead press release
AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

If approved, MAVIRET will be a once-daily, ribavirin-free, 8-week option for patients without cirrhosis and who are new to treatment across all genotypes (GT1-6), who comprise the majority of people living with HCV.1 The European Commission will now review the CHMP opinion and a final decision is expected in Q3 2017.

Published
26 June 2017
From
AbbVie press release
Monitoring the Hepatitis C Epidemic in the United States: What Tools Are Needed to Acheive Elimination?

Hepatitis C is the most common cause of viral hepatitis infections in the US, and it can cause severe health complications such as liver cancer or death. It is estimated that 3.5 million Americans currently have Hepatitis C, yet there exists limited data monitoring or case surveillance conducted to determine the full scope of the disease in the US and to inform efforts to reduce prevalence. This brief focuses on the current state of Hepatitis C data monitoring and surveillance, and identifies new practical and achievable policies and actions to strengthen our capacity to work toward elimination.

Published
20 June 2017
From
O'Neill Institute, Georgetown University
Experts release new recommendations for the elimination of HCV in the U.S.

A recent report from the O’Neill Institute for National and Global Health Law at Georgetown University provides key recommendations for the potential elimination of hepatitis C in the U.S., based upon an expert consultation of 35 diverse stakeholders, including HCV medical and non-medical providers, patient advocates, epidemiologists, and federal HCV policy and program staff.

Published
20 June 2017
From
Healio
Experts question Cochrane review of hepatitis C treatment

A systematic review of hepatitis C direct-acting antiviral (DAA) studies published by the Cochrane Collaboration has been strongly criticised by doctors and advocates for its

Published
15 June 2017
By
Keith Alcorn
Hepatitis C antiviral drugs are effective

The Cochrane analysis casting doubt on this life-saving therapy is flawed and may deter patients from seeking it, say clinicians and scientists

Published
14 June 2017
From
The Guardian
“Findings from hepatitis C study should not deter patients from seeking treatment or governments from funding it” says World Hepatitis Alliance

The World Hepatitis Alliance is concerned that the findings of the Cochrane Review on the new direct acting antiviral (DAA) hepatitis C drugs could have a damaging effect on patient health without a proper understanding of the findings.

Published
13 June 2017
From
World Hepatitis Alliance
← First12345...92Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.